CooperVision Specialty EyeCare’s Procornea DreamLite night lenses have received European approval for slowing the progression of myopia in children and young adults. The orthokeratology contact lens is the latest CooperVision myopia control product to gain the CE Mark, joining EyeDream and Paragon CRT ortho-k designs, MiSight 1-day soft contact lenses, and SightGlass Vision Diffusion Optics Technology spectacle lenses.
“Myopia’s increasing frequency and prevalence is one of the most discussed issues in eye health,” said Dr. Juan Carlos Aragón, President, CooperVision Specialty Eye Care. “But conversation without action will not change the lives of the hundreds of millions of children affected by the issue. That sentiment is echoed by the World Council of Optometry, which recently passed a resolution advising optometrists to incorporate a standard of care for myopia management within their practices.”
DreamLite night lenses can be used for myopia control with children who have a refraction of -0.75 D to -5.00 D and a cylindrical refraction with a maximum of -2.50 D. A 2-year study showed that DreamLite night lenses reduced axial length growth by 63% percent among high myopes compared to the single vision spectacle lens control group—a total reduction of 0.32 mm, according to a 2-year randomized study. The lenses are currently available across Europe, the Middle East, and China.
CooperVision products are used by thousands of ECPs across the region for myopia correction and control. DreamLite ortho-k lenses represent the leading design in the United Kingdom (under the EyeDream brand), and MiSight 1 day soft contact lenses are available in multiple countries for daily wear. Commercialization plans are in progress for SightGlass Vision Diffusion Optics Technology spectacle lenses, which CooperVision acquired earlier this year.
In November 2019, MiSight 1 day became the first and only FDA-approved* soft contact lenses proven to slow myopia progression in children, aged 8-12 at the initiation of treatment, according to a 3-year randomized clinical trial. This pivotal development and subsequent adoption by thousands of influential ECPs has accelerated myopia management in the U.S. and other countries.